HUTCHMED (CHINA) LS-1
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more
Market Cap & Net Worth: HUTCHMED (CHINA) LS-1 (H7T2)
HUTCHMED (CHINA) LS-1 (F:H7T2) has a market capitalization of $2.01 Billion (€1.96 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #6606 globally and #700 in its home market, demonstrating a 4.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HUTCHMED (CHINA) LS-1's stock price €2.28 by its total outstanding shares 859517342 (859.52 Million).
HUTCHMED (CHINA) LS-1 Market Cap History: 2018 to 2026
HUTCHMED (CHINA) LS-1's market capitalization history from 2018 to 2026. Data shows change from $3.91 Billion to $1.99 Billion (-10.87% CAGR).
HUTCHMED (CHINA) LS-1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HUTCHMED (CHINA) LS-1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of H7T2 by Market Capitalization
Companies near HUTCHMED (CHINA) LS-1 in the global market cap rankings as of March 18, 2026.
Key companies related to HUTCHMED (CHINA) LS-1 by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
HUTCHMED (CHINA) LS-1 Historical Marketcap From 2018 to 2026
Between 2018 and today, HUTCHMED (CHINA) LS-1's market cap moved from $3.91 Billion to $ 1.99 Billion, with a yearly change of -10.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.99 Billion | +5.61% |
| 2025 | €1.89 Billion | -19.55% |
| 2024 | €2.35 Billion | -13.07% |
| 2023 | €2.70 Billion | +10.87% |
| 2022 | €2.44 Billion | -54.38% |
| 2021 | €5.34 Billion | +34.44% |
| 2020 | €3.97 Billion | +4.17% |
| 2019 | €3.81 Billion | -2.46% |
| 2018 | €3.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of HUTCHMED (CHINA) LS-1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.01 Billion USD |
| MoneyControl | $2.01 Billion USD |
| MarketWatch | $2.01 Billion USD |
| marketcap.company | $2.01 Billion USD |
| Reuters | $2.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.